STANDARD BIOTOOLS INC. SEC 10-Q Report
Bacaan 1 minit
Standard BioTools Inc., a leading provider of innovative tools and services for life sciences research, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial and operational performance, highlighting key metrics and future outlooks.
Financial Highlights
- Total Revenue: $21.8 million, a decrease of 3% compared to the prior year period due to lower unit sales of instruments and services.
- Gross Profit: $10.6 million, an increase of 2% compared to the prior year period, driven by a favorable product mix with higher consumables revenue.
- Loss from Continuing Operations: $(25.7) million, an improvement from $(30.3) million in the prior year period, reflecting reduced operating expenses.
- Net Loss: $(33.5) million, an improvement from $(45.7) million in the prior year period, primarily due to reductions in operating expenses and restructuring activities.
- Net Loss Per Share: $(0.09), an improvement from $(0.12) in the prior year period, reflecting the overall reduction in net loss.
Business Highlights
- Revenue Segments: The company reported a decline in instrument revenue, primarily due to lower unit sales of the CyTOF XT mass cytometry instrument. However, consumables revenue increased by 18%, offsetting some of the declines in other areas.
- Geographical Performance: Revenue from the Americas decreased, while Europe, Middle East, and Africa (EMEA) showed stable performance. The Asia-Pacific region experienced a decline in revenue, reflecting regional market challenges.
- Sales Units: The company experienced a decrease in unit sales of its CyTOF XT mass cytometry instrument, impacting overall instrument revenue.
- Future Outlook: The company expects to continue investing in its commercial infrastructure and R&D efforts, with a focus on enhancing single-cell and spatial proteomics offerings. Additionally, the company plans to optimize its cost structure and pursue operational efficiencies following the classification of the SomaScan Business as discontinued operations.
SEC Filing: STANDARD BIOTOOLS INC. [ LAB ] - 10-Q - Aug. 15, 2025